Research & Development Overview
FLAMEK's Research and Development (R&D) team is a leader in the area of novel, opioid receptor-targeted therapeutics in Estonia. Using proprietary technology in cloned, human opioid receptors, FLAMEK scientists and clinicians work in close collaboration to discover and develop drug candidates to treat pain and manage the adverse side effects caused by currently available pain treatments.
Today, all marketed opioid analgesic drugs interact with the mu-subtype of opioid receptors in the brain and spinal cord. Activation of these mu opioid receptors in the central nervous system with opioid analgesics such as morphine is very effective in reducing pain perception. Despite the significant clinical benefit of these drugs, the use of morphine-like opioid analgesics is limited by their abuse potential as well as the incidence of serious side effects such as sedation, decreased respiratory function, seizure and gastrointestinal (GI) complications such as postoperative ileus (POI) and opioid bowel dysfunction (OBD).
Hence, there is a significant unmet medical need for potent analgesic medications with reduced side effect liabilities, and for medications to manage the adverse side effects caused by currently available pain treatments.